Peey-sei S. Kok

Camperdown, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

Journal: JTO clinical and research reports

Published: December 09, 2025

Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Journal: JNCI cancer spectrum

Published: July 08, 2024

Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.

Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.

Journal: JCO precision oncology

Published: January 11, 2024

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Journal: Cell reports. Medicine

Published: December 26, 2023

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia.

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia.

Journal: Frontiers in urology

Published: October 08, 2023

A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma.

A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma.

Journal: Internal medicine journal

Published: July 28, 2023

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Journal: Cancers

Published: November 16, 2022

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

Journal: BMJ open

Published: January 26, 2022

Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.

Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.

Journal: Cancer

Published: November 12, 2021

Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.

Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 22, 2021

The validity of progression-free survival 2 as a surrogate trial end point for overall survival.

The validity of progression-free survival 2 as a surrogate trial end point for overall survival.

Journal: Cancer

Published: July 01, 2021

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026